Last updated: May 10, 2024
Sponsor: University of Thessaly
Overall Status: Active - Recruiting
Phase
4
Condition
Pain
Chronic Pain
Treatment
Tramadol
Tapentadol
Clinical Study ID
NCT06269770
Tapentadol
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patients for elective TKR
ASA PS I - III
Exclusion
Exclusion Criteria:
Patient refusal
Cognitive disfunction
Severe psychiatric disease
Under medication with MAO inhibitors, tricyclic antidepressants, serotonin reuptakeinhibitors
Not speaking Greek
Known allergy to the study drugs
Contraindications for any of the study drugs
Chronic renal failure (GFR < 50 ml/h)
Liver failure
Known regular use or misuse of opioids
Pregnant women
Patients undergoing general anesthesia
Study Design
Total Participants: 96
Treatment Group(s): 2
Primary Treatment: Tramadol
Phase: 4
Study Start date:
May 01, 2023
Estimated Completion Date:
June 01, 2025
Study Description
Connect with a study center
University Hospital Of Larissa
Larissa, Thessaly 41110
GreeceActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.